Joseph P Lyssikatos insider trades: Enliven Therapeutics (ELVN) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Joseph reports to the SEC
Open-market buys and sales
36 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | ELVN | ↓ Sell | 5,000 | $29.04 | $145K | Indirect | Feb 10, 2026 (4d) |
| Jan 20, 2026 | ELVN | ↓ Sell | 20,000 | $26.75 | $535K | Indirect | Jan 22, 2026 (2d) |
| Jan 9, 2026 | ELVN | ↓ Sell | 132,500 | $26.23 | $3.5M | Indirect | Jan 12, 2026 (3d) |
| Dec 19, 2025 | ELVN | ↓ Sell | 5,000 | $16.84 | $84K | Indirect | Dec 23, 2025 (4d) |
| Nov 19, 2025 | ELVN | ↓ Sell | 12,500 | $22.33 | $279K | Indirect | Nov 21, 2025 (2d) |
| Oct 20, 2025 | ELVN | ↓ Sell | 12,500 | $22.08 | $276K | Indirect | Oct 22, 2025 (2d) |
| Sep 26, 2025 | ELVN | ↓ Sell | 4,000 | $20.25 | $81K | Indirect | Sep 30, 2025 (4d) |
| Sep 23, 2025 | ELVN | ↓ Sell | 1,500 | $20.03 | $30K | Indirect | Sep 25, 2025 (2d) |
| Sep 19, 2025 | ELVN | ↓ Sell | 7,000 | $19.39 | $136K | Indirect | Sep 23, 2025 (4d) |
| Aug 21, 2025 | ELVN | ↓ Sell | 12,500 | $19.86 | $248K | Indirect | Aug 21, 2025 (0d) |
| Jul 21, 2025 | ELVN | ↓ Sell | 12,500 | $22.29 | $279K | Indirect | Jul 23, 2025 (2d) |
| Jun 20, 2025 | ELVN | ↓ Sell | 12,500 | $21.40 | $267K | Indirect | Jun 24, 2025 (4d) |
| Jun 3, 2025 | ELVN | ↓ Sell | 7,500 | $20.03 | $150K | Indirect | Jun 5, 2025 (2d) |
| May 19, 2025 | ELVN | ↓ Sell | 5,000 | $16.31 | $82K | Indirect | May 21, 2025 (2d) |
| May 2, 2025 | ELVN | ↓ Sell | 7,500 | $20.05 | $150K | Indirect | May 5, 2025 (3d) |
| Apr 21, 2025 | ELVN | ↓ Sell | 5,000 | $16.07 | $80K | Indirect | Apr 23, 2025 (2d) |
| Mar 19, 2025 | ELVN | ↓ Sell | 12,500 | $20.61 | $258K | Indirect | Mar 21, 2025 (2d) |
| Oct 18, 2024 | ELVN | ↓ Sell | 847 | $30.00 | $25K | Indirect | Oct 22, 2024 (4d) |
| Oct 9, 2024 | ELVN | ↓ Sell | 51,145 | $28.11 | $1.4M | Indirect | Oct 10, 2024 (1d) |
| Oct 7, 2024 | ELVN | ↓ Sell | 10,229 | $27.54 | $282K | Indirect | Oct 8, 2024 (1d) |
| Oct 1, 2024 | ELVN | ↓ Sell | 527 | $27.54 | $15K | Indirect | Oct 3, 2024 (2d) |
| Aug 29, 2024 | ELVN | ↓ Sell | 12,000 | $22.49 | $270K | Indirect | Sep 3, 2024 (5d) |
| Jul 31, 2024 | ELVN | ↓ Sell | 3,099 | $27.56 | $85K | Indirect | Aug 2, 2024 (2d) |
| Jul 29, 2024 | ELVN | ↓ Sell | 12,000 | $26.70 | $320K | Indirect | Jul 31, 2024 (2d) |
| Jul 1, 2024 | ELVN | ↓ Sell | 12,000 | $22.89 | $275K | Indirect | Jul 3, 2024 (2d) |
| May 29, 2024 | ELVN | ↓ Sell | 12,000 | $21.73 | $261K | Direct | May 31, 2024 (2d) |
| Apr 29, 2024 | ELVN | ↓ Sell | 12,000 | $17.92 | $215K | Direct | May 1, 2024 (2d) |
| Apr 11, 2024 | ELVN | ↓ Sell | 30,000 | $25.04 | $751K | Direct | Apr 15, 2024 (4d) |
| Apr 1, 2024 | ELVN | ↓ Sell | 12,000 | $18.60 | $223K | Direct | Apr 3, 2024 (2d) |
| Feb 29, 2024 | ELVN | ↓ Sell | 12,000 | $16.42 | $197K | Direct | Mar 4, 2024 (4d) |
| Jan 29, 2024 | ELVN | ↓ Sell | 12,000 | $15.85 | $190K | Direct | Jan 31, 2024 (2d) |
| Dec 29, 2023 | ELVN | ↓ Sell | 12,000 | $14.28 | $171K | Direct | Jan 3, 2024 (5d) |
| Dec 22, 2023 | ELVN | ↓ Sell | 6,566 | $13.07 | $86K | Direct | Dec 26, 2023 (4d) |
| Dec 20, 2023 | ELVN | ↓ Sell | 8,888 | $13.01 | $116K | Direct | Dec 21, 2023 (1d) |
| Nov 3, 2023 | ELVN | ↓ Sell | 8,546 | $13.08 | $112K | Direct | Nov 6, 2023 (3d) |
| Sep 29, 2023 | ELVN | ↓ Sell | 12,000 | $13.62 | $163K | Direct | Oct 3, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ELVN insiders
Open-market trades in the last 12 months
About Joseph P Lyssikatos's insider trades
Joseph P Lyssikatos is Chief Scientific Officer at Enliven Therapeutics (ELVN). Since Sep 29, 2023, Joseph has reported no open-market purchases and 36 sales worth $11.8M on SEC Form 4. In the last 12 months: 5 sales ($4.5M).
Their filings also include option exercises (11 filings), grants and awards (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ELVN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.